glipizide and Weight Gain studies

Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.

Research Excerpts

Excerpt	Relevance	Reference
"5% decrease from baseline) with no weight gain and no hypoglycaemic events with alogliptin 12."	9.22	Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. ( Chaudhari, P; Del Prato, S; Fleck, P; Wilson, C, 2016)
"5% decrease from baseline) with no weight gain and no hypoglycaemic events with alogliptin 12."	5.22	Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. ( Chaudhari, P; Del Prato, S; Fleck, P; Wilson, C, 2016)
"Alogliptin monotherapy maintained glycaemic control comparable to that of glipizide in elderly patients with T2DM over 1 year of treatment, with substantially lower risk of hypoglycaemia and without weight gain."	5.17	Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. ( Fleck, P; Rosenstock, J; Wilson, C, 2013)

Research

Studies (5)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change From Baseline in Body Weight at Week 104

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (40.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Rosenstock, J	1
Wilson, C	2
Fleck, P	2
Del Prato, S	1
Chaudhari, P	1
Seck, TL	1
Engel, SS	1
Williams-Herman, DE	1
Sisk, CM	1
Golm, GT	1
Wang, H	1
Kaufman, KD	1
Goldstein, BJ	1
Selam, JL	1
Woertz, L	1
Lozano, J	1
Robinson, M	1
Chan, E	1
Charles, MA	1
Culler, FL	1
McKean, LP	1
Buchanan, CN	1
Caplan, DB	1
Meacham, LR	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy[NCT00094770]	Phase 3	1,172 participants (Actual)	Interventional	2004-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change from baseline at Week 104 is defined as Week 104 minus Week 0. (NCT00094770)
Timeframe: Baseline and Week 104

Change From Baseline in Body Weight at Week 52

Intervention	Kilograms (Least Squares Mean)
Sitagliptin 100 mg	-1.6
Glipizide	0.7

Change from baseline at Week 52 is defined as Week 52 minus Week 0. (NCT00094770)
Timeframe: Baseline and Week 52

Change From Baseline in HbA1c at Week 104

Intervention	Kilograms (Least Squares Mean)
Sitagliptin 100 mg	-1.5
Glipizide	1.1

HbA1c is measured as percent. Thus, this change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent. (NCT00094770)
Timeframe: Baseline and Week 104

Change From Baseline in HbA1c at Week 52

Intervention	Percent (Least Squares Mean)
Sitagliptin 100 mg	-0.54
Glipizide	-0.51

HbA1c is measured as percent. Thus, this change from baseline reflects the Week 52 HbA1c percent minus the Week 0 HbA1c percent. (NCT00094770)
Timeframe: Baseline and Week 52

Number of Participants With Drug-related LAEs at Week 104

Intervention	Percent (Least Squares Mean)
Sitagliptin 100 mg	-0.67
Glipizide	-0.67

Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs. (NCT00094770)
Timeframe: Baseline to Week 104

Hypoglycemic Events at Week 104

Intervention	Participants (Number)
Sitagliptin 100 mg	18
Glipizide	21

Number of participants who reported 1 or more episodes of the adverse experience of hypoglycemia. (NCT00094770)
Timeframe: Baseline to Week 104

Hypoglycemic Events at Week 52

Intervention	Participants (Number)
	Participants with one or more Hypoglycemic AEs	Total number of Hypoglycemic episodes	Participants with no Hypoglycemic AEs
Glipizide	199	805	385
Sitagliptin 100 mg	31	57	557

Number of participants who reported 1 or more episodes of the adverse experience (AEs) of hypoglycemia. (NCT00094770)
Timeframe: Baseline to Week 52

Number of Participants With Clinical Adverse Experiences (CAEs) at Week 104

Intervention	Participants (Number)
	Participants with one or more Hypoglycemic AEs	Total number of Hypoglycemic episodes	Participants with no Hypoglycemic AEs
Glipizide	187	657	397
Sitagliptin 100 mg	29	50	559

An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. (NCT00094770)
Timeframe: Baseline to Week 104

Number of Participants With Drug-related CAEs at Week 104

Intervention	Participants (Number)
	With CAES	Without CAES
Glipizide	480	104
Sitagliptin 100 mg	452	136

Participants with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs. (NCT00094770)
Timeframe: Baseline to Week 104

Number of Participants With Laboratory Adverse Experiences (LAEs) at Week 104

Intervention	Participants (Number)
	With drug related CAEs	Without drug related CAEs
Glipizide	193	391
Sitagliptin 100 mg	97	491

A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. (NCT00094770)
Timeframe: Baseline to Week 104

Number of Participants With Serious CAEs at Week 104

Intervention	Participants (Number)
	With LAEs	Without LAEs
Glipizide	74	510
Sitagliptin 100 mg	85	503

Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose. (NCT00094770)
Timeframe: Baseline to Week 104

Number of Participants With Serious LAEs at Week 104

Intervention	Participants (Number)
	With serious CAEs	Without serious CAEs
Glipizide	73	511
Sitagliptin 100 mg	64	524

Serious LAEs are any LAEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00094770)
Timeframe: Baseline to Week 104

Article	Year
Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:10 Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor	2013
Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug	2016
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes research and clinical practice, 2011, Volume: 93, Issue:1 Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Gl	2011
The use of glipizide combined with intensive insulin treatment for the induction of remissions in new onset adult type I diabetes. Autoimmunity, 1993, Volume: 16, Issue:4 Topics: Adult; Age of Onset; Algorithms; Blood Glucose; C-Peptide; Combined Modality Therapy; Diabetes Melli	1993

Intervention	Participants (Number)
	With serious LAEs	Without serious LAEs
Glipizide	0	584
Sitagliptin 100 mg	0	588

glipizide and Weight Gain